Apeptico Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 4

Apeptico General Information

Description

Developer of peptide-based products intended to target and treat chronic and life-threatening diseases. The company's products are made by concentrating on synthetically produced protein structures to avoid general risks associated with gene and cell technologies, enabling doctors to significantly reduce cost and shorten time to market.

Contact Information

Website
www.apeptico.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Mariahilfer Straße 136
  • Top 1.15
  • Vienna, 1150
  • Austria
+43 0664 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Apeptico Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 10-Oct-2017 00.000 Completed Generating Revenue
4. Grant 08-Jul-2013 00000 00.000 Completed Generating Revenue
3. Early Stage VC 16-May-2012 00.000 Completed Startup
2. Early Stage VC (Series A) 05-Aug-2010 $3.87M $5.23M Completed Startup
1. Seed Round 29-May-2009 $1.37M $1.37M Completed Startup
To view Apeptico’s complete valuation and funding history, request access »

Apeptico Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of peptide-based products intended to target and treat chronic and life-threatening diseases. The company's pr
Drug Discovery
Vienna, Austria
00.000
00000000000 00.000

00000 00

odo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugia
0000 000000000
Copenhagen, Denmark
00 As of 0000
00.000
0000000000 0 00.000

0000000

ore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip
0000000000000
Stockholm, Sweden
0 As of 0000
000.00
00.00 0000-00-00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Apeptico Competitors (70)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Antag Therapeutics Venture Capital-Backed Copenhagen, Denmark 00 00.000 0000000000 0 00.000
0000000 000000 Venture Capital-Backed Stockholm, Sweden 0 000.00 0000000000 0 000.00
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
00000 Formerly VC-backed Cambridge, MA 000 00000 000000&0
0000000 0000000000 Formerly VC-backed Toronto, Canada 0 00.000 000000&0 00.000
You’re viewing 5 of 70 competitors. Get the full list »

Apeptico Patents

  • 124

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 13

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Apeptico Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2018528221-A Cyclic polypeptides for the treatment of pha type 1b Pending 14-Sep-2015 000000000
CA-2998443-A1 Cyclic polypeptide for the treatment of pha type 1b Abandoned 14-Sep-2015 000000000
ES-2805698-T3 Cyclic polypeptide for the treatment of pha type 1b Active 14-Sep-2015 000000000
EP-3349779-B1 Cyclic polypeptide for the treatment of pha type 1b Active 14-Sep-2015 000000000
EP-3349779-A1 Cyclic polypeptide for the treatment of pha type 1b Granted 14-Sep-2015 A61K38/12
To view Apeptico’s complete patent history, request access »

Apeptico Executive Team (4)

Name Title Board Seat Contact Info
Bernhard Fischer Chief Executive Officer & Managing Director
Hermann Mascher Executive
Rudolf Lucas Scientific Advisor
You’re viewing 3 of 4 executive team members. Get the full list »

Apeptico Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
The Austrian Research Promotion Agency Government 000 0000 000000 0
BioBac Angel Group Minority 000 0000 000000 0
INiTS Universitäres Gründerservice Accelerator/Incubator Minority 000 0000 000000 0
The BioScience Ventures Group Venture Capital Minority 000 0000 000000 0
To view Apeptico’s complete investors history, request access »

Ready to get started?

Request a free trial